2022 hasn’t been a great year for all kinds of tech stocks, and certainly biotech has taken its fair share of lumps as interest rates have continued to dry up funding. That hasn’t stopped the innovation that makes biotech such an appealing space, however. There are still significant steps forward being taken in genetics and [...] The post Gene Editing Stock in ARKG Gets Buy Rating appeared first on ETF Trends .